Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.

ABSTRACT:

Objectives

To examine the accessibility and quality of drug company payment data in Europe.

Design

Comparative policy review of payment data in countries with different regulatory approaches to disclosure.

Setting

37 European countries.

Participants

European Federation of Pharmaceutical Industries and Associations, its trade group and their drug company members; eurosfordocs.eu, an independent database integrating payments disclosed by companies and trade groups; regulatory bodies overseeing payment disclosure.

Main outcome measures

Regulatory approaches to disclosure (self-regulation, public regulation, combination of the two); data accessibility (format, structure, searchability, customisable summary statistics, downloadability) and quality (spectrum o

SUBMITTER: Ozieranski P 

PROVIDER: S-EPMC8679071 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature